Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Ontario faces more vaccine delays as it struggles to tame third COVID-19 wave

Published 2021-04-19, 05:00 p/m
Updated 2021-04-19, 05:06 p/m

TORONTO, April 19 (Reuters) - Ontario Premier Doug Ford said on Monday the province expects to face a delay in the supply of AstraZeneca (NASDAQ:AZN) Plc ANZ.L COVID-19 vaccine, dealing another blow to its efforts to contain a punishing third wave of the pandemic.

"In addition to the delayed and cut Moderna shipments, the Premier was notified today by our officials to be prepared for delays to two shipments of AstraZeneca expected from the federal government later this month and next," a statement from Ford's office said.

Canada's most-populous province said on Sunday it would lower the minimum age for recipients of the AstraZeneca vaccine to 40 from 55. announced 4,447 new cases on Monday, with a 10.5% positivity rate and 19 more deaths. The rising caseload - 755 COVID-19 patients in intensive care on Monday - has pushed the province's hospitals to the brink.

On Friday, the government announced measures including closing its borders with the provinces of Quebec and Manitoba. But the following day it reversed its decision to close playgrounds and amended its granting of extra powers to police to enforce a stay-at-home order. Inc MRNA.O said last week that vaccine shipments to Canada would be cut to 650,000 doses from 1.2 million.

Before Ontario decided to lower the age group for AstraZeneca vaccines, doctors and pharmacists had expressed concern that not enough people were signing up to take the AstraZeneca shot, citing blood clot fears. Two people in Canada have developed clots after receiving the shot and are recovering.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Nadjla Banaei, client care coordinator at the South Riverdale Community Health Centre in Toronto, has had several clients express concerns about the AstraZeneca vaccine. They may have underlying health conditions and worry about what they have read, she said.

"We've had several people say: 'No, no thanks, we'll wait for Pfizer (NYSE:PFE) and Moderna,'" Banaei said.

The move to lower the age group expands the pool of potential AstraZeneca recipients but does not necessarily quell fears around it, she said.

"Why did they drop the age all of a sudden? What are we supposed to communicate to people? ... Of course, with all these changes, people are going to be hesitant."

Federal Health Minister Patty Hajdu said over the weekend that the provinces were free to offer AstraZeneca to anyone over 18.

Alberta and Manitoba have also said they would lower the age.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.